Oman Breast Cancer Core Needle Biopsy Market Report: Size, Share, Growth Drivers, Trends, Opportunities & Forecast 2025-2030

Oman Breast Cancer Core Needle Biopsy Market valued at USD 15M, driven by rising breast cancer incidence and advancements in diagnostic technologies for early detection.

The Oman Breast Cancer Core Needle Biopsy Market is valued at USD 15 million, based on a five-year historical analysis. This growth is primarily driven by the rising incidence of breast cancer, which now accounts for over one-third of new cancer cases among Omani women, increasing public awareness about early detection, and ongoing advancements in biopsy technologies. The healthcare sector’s emphasis on improving diagnostic accuracy and patient outcomes has further propelled the demand for core needle biopsy procedures, with late-stage diagnosis remaining a significant challenge and driver for improved screening uptake.

Muscat, Salalah, and Sohar continue to dominate the market due to their advanced healthcare infrastructure and concentration of specialized medical facilities. These cities have benefited from substantial investments in healthcare, resulting in enhanced access to diagnostic services and a higher rate of breast cancer screening initiatives. The presence of tertiary care hospitals and cancer centers in these urban hubs has contributed to increased adoption of core needle biopsy procedures.

In 2023, the Omani government strengthened its commitment to breast cancer control by implementing the “National Early Detection and Screening for Breast Cancer Guideline” (MOH/DGHS&P/GUD/003/Vers. 02, Ministry of Health, 2025). This binding instrument mandates population-based screening, subsidized diagnostic services, and public awareness campaigns, with operational protocols for referral, compliance, and reporting. The program aims to increase early detection rates and ensure standardized access to core needle biopsy procedures nationwide.

Oman Breast Cancer Core Needle Biopsy Market Segmentation

By Type:

The market is segmented by biopsy procedure, including Core Needle Biopsy, Vacuum-Assisted Biopsy, Fine Needle Aspiration Biopsy, Stereotactic-Guided Biopsy, MRI-Guided Biopsy, and Others. Core Needle Biopsy remains the most widely used technique, favored for its diagnostic accuracy and minimally invasive nature. The growing preference for less invasive procedures and the increasing number of breast cancer cases have reinforced the dominance of core needle biopsy in clinical practice. Vacuum-assisted and image-guided techniques are gaining traction as healthcare providers seek improved sample quality and patient comfort.

By End-User:

The end-user segmentation includes Hospitals, Diagnostic Laboratories, Cancer Research Centers, Academic & Research Institutes, and Others. Hospitals are the leading end-users, providing comprehensive cancer care and possessing the infrastructure required for core needle biopsies. The expansion of specialized oncology departments and multidisciplinary cancer centers within hospitals has further driven the growth of this segment. Diagnostic laboratories and research centers are also increasing their role in biopsy services as part of broader cancer screening and research initiatives.

Oman Breast Cancer Core Needle Biopsy Market Competitive Landscape

The Oman Breast Cancer Core Needle Biopsy Market is characterized by a dynamic mix of regional and international players. Leading participants such as Siemens Healthineers, Hologic, Inc., BD (Becton, Dickinson and Company), GE HealthCare, Canon Medical Systems Corporation, Fujifilm Holdings Corporation, Argon Medical Devices, Inc., Devicor Medical Products, Inc. (Leica Biosystems), Medtronic plc, Cook Medical LLC, Cardinal Health, Inc., Merit Medical Systems, Inc., Olympus Corporation, Philips Healthcare, Stryker Corporation contribute to innovation, geographic expansion, and service delivery in this space.

Oman Breast Cancer Core Needle Biopsy Market Industry Analysis

Growth Drivers

Increasing Incidence of Breast Cancer:

The incidence of breast cancer in Oman has been rising, with approximately 1,200 new cases reported annually as of 2023. This increase is attributed to factors such as lifestyle changes and genetic predispositions. The World Health Organization (WHO) indicates that breast cancer accounts for 25% of all cancer cases in women in Oman, necessitating improved diagnostic methods like core needle biopsy to enhance early detection and treatment outcomes.

Advancements in Biopsy Techniques:

Recent technological advancements have significantly improved core needle biopsy techniques, making them less invasive and more accurate. For instance, the introduction of ultrasound-guided biopsies has increased diagnostic accuracy rates to over 90%. According to the Ministry of Health in Oman, these innovations have led to a 30% increase in the adoption of biopsy procedures, as healthcare providers seek to enhance patient care and reduce recovery times.

Rising Awareness and Screening Programs:

Public awareness campaigns and screening programs have been instrumental in promoting early detection of breast cancer in Oman. The government has invested around OMR 2 million in awareness initiatives in future, leading to a 40% increase in women participating in screening programs. This heightened awareness is driving demand for core needle biopsies, as more women seek timely and accurate diagnostic services.

Market Challenges

High Cost of Biopsy Procedures:

The cost of core needle biopsy procedures in Oman can be prohibitive, with prices ranging from OMR 150 to OMR 300 per procedure. This financial barrier limits access for many patients, particularly in lower-income demographics. The high costs are often compounded by the need for additional imaging studies, which can further deter patients from seeking necessary diagnostic services.

Limited Access to Healthcare Facilities:

Access to healthcare facilities in Oman remains a significant challenge, particularly in rural areas. According to the Ministry of Health, only 60% of the population lives within 30 minutes of a healthcare facility capable of performing core needle biopsies. This geographical disparity results in delayed diagnoses and treatment, adversely affecting patient outcomes and overall market growth.

Oman Breast Cancer Core Needle Biopsy Market Future Outlook

The future of the Oman breast cancer core needle biopsy market appears promising, driven by ongoing advancements in medical technology and increased government support for healthcare initiatives. As the healthcare infrastructure expands, more facilities will be equipped to offer these essential diagnostic services. Additionally, the integration of artificial intelligence in diagnostic processes is expected to enhance accuracy and efficiency, further encouraging patient engagement and participation in screening programs.

Market Opportunities

Growth in Medical Tourism:

Oman is positioning itself as a medical tourism destination, attracting patients from neighboring countries seeking advanced cancer treatment options. The government aims to increase medical tourism revenue to OMR 500 million by future, creating opportunities for core needle biopsy services to cater to international patients seeking high-quality care.

Development of Innovative Biopsy Devices:

The market for innovative biopsy devices is expanding, with investments in research and development projected to reach OMR 1 million in future. This focus on innovation is expected to lead to the introduction of more efficient and patient-friendly biopsy technologies, enhancing the overall diagnostic experience and increasing adoption rates among healthcare providers.